NO327465B1 - 2-oksasolaminer og deres anvendelse samt farmasoytisk sammensetning - Google Patents

2-oksasolaminer og deres anvendelse samt farmasoytisk sammensetning Download PDF

Info

Publication number
NO327465B1
NO327465B1 NO20043799A NO20043799A NO327465B1 NO 327465 B1 NO327465 B1 NO 327465B1 NO 20043799 A NO20043799 A NO 20043799A NO 20043799 A NO20043799 A NO 20043799A NO 327465 B1 NO327465 B1 NO 327465B1
Authority
NO
Norway
Prior art keywords
alkyl
optionally substituted
hydroxy
alkoxy
cycloalkyl
Prior art date
Application number
NO20043799A
Other languages
English (en)
Norwegian (no)
Other versions
NO20043799L (no
Inventor
Alexander William Oxford
Neil Victor Harris
Anthony Richard Borman
Lyle Kenneth Clark
Ann Janet Archer
George Hynd
Amanda Aley
Original Assignee
Pharmagene Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmagene Lab Ltd filed Critical Pharmagene Lab Ltd
Publication of NO20043799L publication Critical patent/NO20043799L/no
Publication of NO327465B1 publication Critical patent/NO327465B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20043799A 2002-02-13 2004-09-10 2-oksasolaminer og deres anvendelse samt farmasoytisk sammensetning NO327465B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0203412.2A GB0203412D0 (en) 2002-02-13 2002-02-13 5-HT 2B receptor antagonists
PCT/GB2003/000552 WO2003068226A1 (en) 2002-02-13 2003-02-11 2-oxazolamines and their use as 5-ht2b receptor antagonists

Publications (2)

Publication Number Publication Date
NO20043799L NO20043799L (no) 2004-09-10
NO327465B1 true NO327465B1 (no) 2009-07-06

Family

ID=9930999

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043799A NO327465B1 (no) 2002-02-13 2004-09-10 2-oksasolaminer og deres anvendelse samt farmasoytisk sammensetning

Country Status (17)

Country Link
US (1) US7429607B2 (enExample)
EP (1) EP1474140B1 (enExample)
JP (1) JP4439266B2 (enExample)
KR (1) KR20040084905A (enExample)
CN (1) CN1633291A (enExample)
AU (1) AU2003207297B2 (enExample)
CA (1) CA2472762A1 (enExample)
DE (1) DE60317632T2 (enExample)
EA (1) EA200401077A1 (enExample)
GB (1) GB0203412D0 (enExample)
IL (1) IL163110A (enExample)
MX (1) MXPA04007738A (enExample)
NO (1) NO327465B1 (enExample)
NZ (1) NZ534539A (enExample)
PL (1) PL370221A1 (enExample)
WO (1) WO2003068226A1 (enExample)
ZA (1) ZA200406010B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1299948B1 (it) 1998-04-02 2000-04-04 Azionaria Costruzioni Acma Spa Metodo e dispositivo per la formazione di gruppi di articoli appiattiti.
US20050176791A1 (en) * 2002-02-13 2005-08-11 Oxford Alexander W. 5-HT2B receptor antagonists
JP2006528617A (ja) * 2003-07-24 2006-12-21 ファーマジーン ラボラトリーズ リミテッド 5−ht2b受容体アンタゴニスト
CA2557158A1 (en) 2004-02-20 2005-09-01 Astellas Pharma Inc. Prophylactic antimigraine agents
SE0400850D0 (sv) * 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
WO2005097113A2 (en) * 2004-04-08 2005-10-20 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
AU2005289100B2 (en) 2004-09-29 2011-11-03 Bayer Healthcare Llc Thermodynamically stable form of bay 43-9006 tosylate
WO2014085413A1 (en) * 2012-11-28 2014-06-05 Temple University - Of The Commonwealth System Of Higher Education Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2b activity modulators
KR101592068B1 (ko) 2013-11-08 2016-02-05 순천향대학교 산학협력단 플라즈마 아포리포프로테인 h를 포함하는 아스피린 과민성 호흡계 질환 및 아스피린 내성 천식 구별 진단용 마커 및 구별 진단용 키트
CN116789549A (zh) * 2023-06-16 2023-09-22 山东科源化工有限公司 一种羟基乙酸乙烯酯的制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0658559A1 (de) * 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren
US5663178A (en) 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
JPH09510216A (ja) 1994-03-11 1997-10-14 イーライ・リリー・アンド・カンパニー 5−ht▲下2b▼受容体に関連する病態を治療するための方法
DE69717091T2 (de) * 1996-04-03 2003-07-31 Takeda Chemical Industries, Ltd. Oxazole derivate,ihre herstellung und verwendung
US5958934A (en) 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US5952331A (en) 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
DE60005526T2 (de) 1999-07-30 2004-07-01 Pharmagene Laboratories Ltd. Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes
AR035016A1 (es) * 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.

Also Published As

Publication number Publication date
WO2003068226A1 (en) 2003-08-21
AU2003207297B2 (en) 2008-11-06
CA2472762A1 (en) 2003-08-21
AU2003207297A1 (en) 2003-09-04
AU2003207297A2 (en) 2003-09-04
IL163110A (en) 2010-12-30
EP1474140B1 (en) 2007-11-21
EP1474140A1 (en) 2004-11-10
EA200401077A1 (ru) 2005-06-30
ZA200406010B (en) 2005-06-08
US7429607B2 (en) 2008-09-30
KR20040084905A (ko) 2004-10-06
GB0203412D0 (en) 2002-04-03
DE60317632D1 (de) 2008-01-03
NZ534539A (en) 2006-02-24
DE60317632T2 (de) 2008-10-30
JP2005528341A (ja) 2005-09-22
JP4439266B2 (ja) 2010-03-24
NO20043799L (no) 2004-09-10
MXPA04007738A (es) 2004-10-15
PL370221A1 (en) 2005-05-16
US20040010022A1 (en) 2004-01-15
CN1633291A (zh) 2005-06-29

Similar Documents

Publication Publication Date Title
JP5788496B2 (ja) 複素環化合物およびその用途
AU728812B2 (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
AU2014212431B2 (en) Amides as modulators of sodium channels
WO2020146682A1 (en) Carboxamides as modulators of sodium channels
AU2008341173B2 (en) Bis- (sulf onylamino) derivatives for use in therapy
CA3221960A1 (en) Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
AU2014290411A1 (en) Sulfonamides as modulators of sodium channels
JP2002513387A (ja) 選択的β▲下3▼アドレナリン作動性アゴニスト
JP2009538358A (ja) 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター
JP2006528617A (ja) 5−ht2b受容体アンタゴニスト
US6011048A (en) Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity
JP4439266B2 (ja) 2−オキサゾールアミンおよび5−ht2b受容体アンタゴニストとしてのその使用
JP2008545686A (ja) 5ht6受容体を調節する新規な8−スルホニルアミノ−3アミノ置換クロマンまたはテトラヒドロナフタレン誘導体
JPH10139780A (ja) 新規な複素環式アミノメチル化合物、これらの製造方法及びこれらを含む医薬組成物
JP2005526720A (ja) 5−ht2b受容体アンタゴニスト
US7166624B2 (en) Peptide deformylase inhibitors
US20050176791A1 (en) 5-HT2B receptor antagonists
BRPI0619282A2 (pt) sal de p-toluenossulfonato, sal, composição farmacêutica, método de modular ppar e uso de um sal
WO2005097113A2 (en) 5-ht2b receptor antagonists
MXPA06010329A (en) Substituted morpholine and thiomorpholine derivatives
OA17449A (en) Pyridone amides as modulators of sodium channels.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees